MIRA De-Risks Obesity Drug Dose Selection with Positive 7-Day Dog Study for SKNY-1
MIRA sits 19% above its 52-week low of $0.6.
Summary
MIRA Pharmaceuticals reported positive preclinical results for SKNY-1, an oral obesity drug designed to preserve lean body mass. The data supports advancement toward IND-enabling studies, a key milestone for a company facing Nasdaq delisting risk.
Key Events · Product Development and Regulatory · MIRA
-
Positive SKNY-1 Dog Study Results
A 7-day repeated-dose study in Beagle dogs showed dose-dependent systemic exposure and rapid oral absorption for SKNY-1, an investigational oral obesity treatment.
-
De-Risked Dose Selection for GLP Studies
The toxicokinetic findings provide confidence in dose selection for the planned GLP-compliant toxicology program, a prerequisite for IND-enabling development.
-
Pipeline Progress Amid Nasdaq Deficiency
The positive data arrives one week after MIRA received a Nasdaq deficiency letter for its stock trading below $1, highlighting the importance of advancing its pipeline to restore investor confidence.
-
Next Steps: IND-Enabling Studies
MIRA will use these results to design GLP toxicology studies, with additional preclinical efficacy and safety work required before an IND submission.
Analysis · MIRA · Life Sciences
MIRA announced positive toxicokinetic data from a 7-day dog study of its obesity candidate SKNY-1, showing dose-dependent exposure and rapid absorption. These findings de-risk dose selection for the upcoming GLP toxicology program, a critical step toward an IND filing. The news comes just days after a Nasdaq deficiency letter for sub-$1 trading, making pipeline progress essential to sustaining investor confidence and the company's listing.
At the time of this filing, MIRA was trading at $0.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $27.6M. The 52-week trading range was $0.60 to $2.45. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.